Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Scarmo, Stephanie ^a   Afanasyeva, Yelena ^a   Lenner, Per ^b   Koenig, Karen L ^a   Horst, Ronald L ^c   Clendenen, Tess V ^a   Arslan, Alan A ^a   Chen, Yu ^a   Hallmans, Göran ^d   Lundin, Eva ^d   Rinaldi, Sabina ^e   Toniolo, Paolo ^a   Shore, Roy E ^a,f   Zeleniuch Jacquotte, Anne ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c Heartland Assays Inc   (United States)

^d UMEÅ UNIVERSITY   (Sweden)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREMENOPAUSE; AGED; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL; SWEDEN;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PREMENOPAUSE; RISK FACTORS; SWEDEN; VITAMIN D;

EID: 84874199657     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3390     Document Type: Article

References (47)

1. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004, 80:1721S-1724S.
2. Bertone-Johnson ER. Vitamin D and breast cancer. Ann Epidemiol 2009, 19:462-467. 10.1016/j.annepidem.2009.01.003, 19230714.
3. Institute of Medicine; Food and Nutrition Board Dietary Reference Intakes for Calcium and Vitamin D 2010, Washington, DC: Institute of Medicine; Food and Nutrition Board, Ross AC, Taylor CL, Yaktine AL, Del Valle HB, Institute of Medicine; Food and Nutrition Board.
4. Friedrich M, Diesing D, Cordes T, Fischer D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick MF, Reichrath J. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res 2006, 26:2615-2620.
5. Davis CD. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr 2008, 88:565S-569S.
6. Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr 2008, 88:500S-506S.
7. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003, 133:2425S-2433S.
8. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA, Women's Health Initiative Investigators Calcium plus vitamin d supplementation and the risk of breast cancer. J Natl Cancer Inst 2008, 100:1581-1591. 10.1093/jnci/djn360, 2673920, 19001601, Women's Health Initiative Investigators.
9. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2008, 17:889-894. 10.1158/1055-9965.EPI-07-2594, 18381472.
10. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 2009, 11:R64. 10.1186/bcr2356, 2750126, 19715600.
11. Agborsangaya CB, Surcel HM, Toriola AT, Pukkala E, Parkkila S, Tuohimaa P, Lukanova A, Lehtinen M. Serum 25-hydroxyvitamin D at pregnancy and risk of breast cancer in a prospective study. Eur J Cancer 2010, 46:467-470. 10.1016/j.ejca.2009.11.019, 20022237.
12. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer 2010, 127:2159-2168. 10.1002/ijc.25215, 20112341.
13. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res 2011, 13:R50. 10.1186/bcr2880, 3218936, 21569367.
14. Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat 2012, 133:1077-1088. 10.1007/s10549-012-2012-x, 3396331, 22415479.
15. Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010, 19:2341-2350. 10.1158/1055-9965.EPI-10-0264, 20826834.
16. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1991-1997. 10.1158/1055-9965.EPI-04-0722, 16103450.
17. Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2009, 18:2655-2660. 10.1158/1055-9965.EPI-09-0531, 19789365.
18. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:827-838.
19. International Agency for Research on Cancer Vitamin D and cancer. IARC Working Group Reports 2008, 5:143-148. Lyon, France: International Agency for Research on Cancer, International Agency for Research on Cancer.
20. Toniolo PG, Pasternack BS, Shore RE, Sonnenschein E, Koenig KL, Rosenberg C, Strax P, Strax S. Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat 1991, 18(Suppl 1):S23-26.
21. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, Lindahl B, Rolandsson O, Söderberg S, Nilsson M, Johansson I, Weinehall L. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. Scand J Public Health Suppl 2003, 61:18-24.
22. Kato I, Toniolo P, Koenig KL, Kahn A, Schymura M, Zeleniuch-Jacquotte A. Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol 1999, 149:372-378. 10.1093/oxfordjournals.aje.a009823, 10025481.
23. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 2009, 42:1549-1556. 10.1016/j.clinbiochem.2009.07.013, 19631201.
24. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004, 90:153-159. 10.1038/sj.bjc.6601517, 2395327, 14710223.
25. Rinaldi S, Déchaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Secreto G, Ciampi A, Riboli E, Kaaks R. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001, 10:757-765.
26. Borkowf CB, Albert PS, Abnet CC. Using lowess to remove systematic trends over time in predictor variables prior to logistic regression with quantile categories. Stat Med 2003, 22:1477-1493. 10.1002/sim.1507, 12704611.
27. Brock K, Huang WY, Fraser DR, Ke L, Tseng M, Stolzenberg-Solomon R, Peters U, Ahn J, Purdue M, Mason RS, McCarty C, Ziegler RG, Graubard B. Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. J Steroid Biochem Mol Biol 2010, 121:462-466. 10.1016/j.jsbmb.2010.03.091, 2906665, 20399270.
28. McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, Kolonel L, Laden F, Le Marchand L, Purdue M, Snyder K, Stevens VL, Stolzenberg-Solomon R, Virtamo J, Yang G, Yu K, Zheng W, Albanes D, Ashby J, Bertrand K, Cai H, Chen Y, Gallicchio L, Giovannucci E, Jacobs EJ, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, et al. Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010, 172:21-35. 10.1093/aje/kwq113, 2892536, 20562191.
29. Winzer BM, Whiteman DC, Reeves MM, Paratz JD. Physical activity and cancer prevention: a systematic review of clinical trials. Cancer Causes Control 2011, 22:811-826. 10.1007/s10552-011-9761-4, 21461921.
30. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007, 16:219-242. 10.1177/0962280206074463, 17621469.
31. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010, 121:469-477. 10.1007/s10549-009-0593-9, 19851861.
32. Chlebowski RT. Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res 2011, 13:217. 10.1186/bcr2846, 3236325, 21884640.
33. Janowsky EC, Lester GE, Weinberg CR. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 1999, 2:283-291.
34. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss E, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study. Carcinogenesis 2008, 29:93-99.
35. Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2009, 124:250-255. 10.1002/ijc.23904, 18839430.
36. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009, 2:598-604.
37. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005, 41:1164-1169. 10.1016/j.ejca.2005.01.017, 15911240.
38. Dorgan J, Stanczyk F, Kahle L, Brinton L. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2010, 12:R98. 10.1186/bcr2779, 3046441, 21087481.
39. Fedirko V, Torres-Mejía G, Ortega-Olvera C, Biessy C, Angeles-Llerenas A, Lazcano-Ponce E, Saldaña-Quiroz VA, Romieu I. Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women. Cancer Causes Control 2012, 23:1149-1162. 10.1007/s10552-012-9984-z, 22622862.
40. Welsh J, Wietzke J, Zinser G, Smyczek S, Romu S, Tribble E, Welsh J, Byrne B, Narvaez C. Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 2002, 83:85-92. 10.1016/S0960-0760(02)00277-7, 12650704.
41. Zhang X, Giovannucci E. Calcium, vitamin D and colorectal cancer chemoprevention. Best Pract Res Clin Gastroenterol 2011, 25:485-494. 10.1016/j.bpg.2011.10.001, 22122765.
42. Neuhouser ML, Manson JE, Millen A, Pettinger M, Margolis K, Jacobs ET, Shikany JM, Vitolins M, Adams-Campbell L, Liu S, LeBlanc E, Johnson KC, Wactawski-Wende J. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 2012, 175:673-684. 10.1093/aje/kwr350, 22362582.
43. Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, Robbins J, LaCroix AZ, LeBoff MS, Jackson RD. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr 2010, 91:1324-1335. 10.3945/ajcn.2009.28908, 2854906, 20219959.
44. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Koenig KL, Kolonel LN, Laden F, McCullough ML, Parisi D, Purdue MP, Shu XO, Snyder K, Stolzenberg-Solomon RZ, Tworoger SS, Varanasi A, Virtamo J, Wilkens LR, Xiang YB, Yu K, Zeleniuch-Jacquotte A, Zheng W, Abnet CC, Albanes D, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010, 172:10-20. 10.1093/aje/kwq116, 2892539, 20562188.
45. Lukanova A, Andersson R, Wulff M, Zeleniuch-Jacquotte A, Grankvist K, Dossus L, Afanasyeva Y, Johansson R, Arslan AA, Lenner P, Wadell G, Hallmans G, Toniolo P, Lundin E. Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study. Am J Epidemiol 2008, 168:1284-1291. 10.1093/aje/kwn254, 2587527,2587527, 18936438.
46. Richardson BE, Hulka BS, David Peck JL, Hughes CL, van den Berg BJ, Christianson RE, Calvin JA. Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 1998, 148:719-727. 10.1093/oxfordjournals.aje.a009691, 9786226.
47. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010, 171:903-908. 10.1093/aje/kwq005, 20219763.